We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

63 hedge funds and large institutions have $21.5M invested in Galectin Therapeutics in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 16

3% less funds holding

Funds holding: 65 → 63 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

63% less capital invested

Capital invested by funds: $58.6M → $21.5M (-$37.1M)

72% less call options, than puts

Call options by funds: $326K | Put options by funds: $1.15M

Holders
63
Holders Change
-2
Holders Change %
-3.08%
% of All Funds
1.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
22
Reduced
16
Closed
12
Calls
$326K
Puts
$1.15M
Net Calls
-$828K
Net Calls Change
+$717K

Top Buyers

Rank Fund Capital Flow
1
CCA
Catalyst Capital Advisors
New York
+$5.26M
2
Northern Trust
Northern Trust
Illinois
+$1.11M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$742K
4
ARTA
A.R.T. Advisors
New York
+$633K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$430K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$4.14M
2
CAM
Cormorant Asset Management
Massachusetts
-$2.72M
3
Allianz Asset Management
Allianz Asset Management
Germany
-$1.92M
4
DADC
D.A. Davidson & Co
Montana
-$581K
5
Macquarie Group
Macquarie Group
Australia
-$467K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCA
1
Catalyst Capital Advisors
New York
$3.4M +$5.26M +675,000 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$3M +$742K +95,258 +19%
CAM
3
Cormorant Asset Management
Massachusetts
$2.27M -$2.72M -349,600 -44%
BFA
4
BlackRock Fund Advisors
California
$2.19M -$143K -18,414 -4%
Northern Trust
5
Northern Trust
Illinois
$1.04M +$1.11M +142,337 +222%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$885K +$430K +55,243 +46%
State Street
7
State Street
Massachusetts
$879K +$29.1K +3,738 +2%
BIT
8
BlackRock Institutional Trust
California
$861K -$232K -29,847 -15%
Neuberger Berman Group
9
Neuberger Berman Group
New York
$819K – – –
BCA
10
Benchmark Capital Advisors
New York
$672K +$348K +44,650 +50%
DADC
11
D.A. Davidson & Co
Montana
$601K -$581K -74,558 -38%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$553K +$841 +108 +0.1%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$421K +$50.2K +6,442 +8%
ARTA
14
A.R.T. Advisors
New York
$408K +$633K +81,224 New
CS
15
Credit Suisse
Switzerland
$368K +$211K +27,114 +59%
TCIM
16
TIAA CREF Investment Management
New York
$325K -$12.5K -1,611 -2%
BIM
17
BlackRock Investment Management
Delaware
$269K +$12K +1,539 +3%
California State Teachers Retirement System (CalSTRS)
18
California State Teachers Retirement System (CalSTRS)
California
$166K +$1.47K +189 +0.6%
Deutsche Bank
19
Deutsche Bank
Germany
$158K +$670 +86 +0.3%
Charles Schwab
20
Charles Schwab
California
$133K – – –
Morgan Stanley
21
Morgan Stanley
New York
$130K -$459K -58,904 -69%
TA
22
Teachers Advisors
New York
$128K – – –
California Public Employees Retirement System
23
California Public Employees Retirement System
California
$118K – – –
NPF
24
Norris Perne & French
Michigan
$111K +$171K +22,000 New
Macquarie Group
25
Macquarie Group
Australia
$101K -$467K -60,000 -75%
1
2 3

GALT Hedge Fund Activity: Q3 2014 in Review

63 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2014, worth a combined $21.5M — down 63% from $58.6M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of GALT and 10 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 22 added.

The largest buyer was Catalyst Capital Advisors, opening a new position worth an estimated $5.26M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.14M sold.

  • 63 institutional investors held Galectin Therapeutics (GALT) as of Q3 2014, down from 65 in Q2 2014.
  • Funds reported $21.5M of Galectin Therapeutics stock for Q3 2014, down 63% quarter-over-quarter.
  • 10 funds opened new Galectin Therapeutics positions in Q3 2014 and 12 closed out, a net change of -2 holders.
  • The largest Galectin Therapeutics buyer in Q3 2014 was Catalyst Capital Advisors, an estimated $5.26M added.
  • The largest Galectin Therapeutics seller in Q3 2014 was Baker Bros. Advisors, an estimated $4.14M sold.

Based on aggregated 13F filings for Q3 2014.